Former Corindus CEO Toland joins medtech investment firm
As a partner and entrepreneur in residence (EIR), Toland is slated to help in the discovery, development and nurturing of new startups with high-growth potential. He will also have the flexibility to function in a number of roles with these companies, including consultant, board member or other executive leadership positions, according to a news release.
Toland’s tenure at Corindus, a recent Siemens Healthcare portfolio purchase, included leading the company to develop and launch its CorPath GRX, which Corindus currently touts as the only FDA-cleared and CE-Marked robotic system for endovascular coronary and peripheral vascular interventions.
Before Corindus, Toland served as senior VP at Boston Scientific, working on the company’s commercial impact across all business segments, having also held roles with the company’s sales operations for interventional cardiology, cardiac rhythm management, peripheral interventions and electrophysiology.
“The time is now for advanced technology to fundamentally reshape healthcare,” Toland said in the release. “In my time at Corindus, I saw firsthand how the world, partially in response to COVID, has embraced technology, not only from within the clinical community but at a societal level.
“My colleagues at BioStar are uniquely focused on finding and developing innovative companies ready to leverage AI, Deep Learning, Robotics and other transformative technologies to address a wide range of healthcare inefficiencies and inequities.”
Toland is set to join a BioStar team that has invested in more than 30 medical device startups, with nearly half of them acquired by major medical device manufacturers, including Boston Scientific, Medtronic and Covidien.
“Having been an early investor in Corindus, the BioStar team and I have had the privilege of working with Mark for several years and experiencing firsthand his innate leadership ability, and we’re thrilled to have him aboard,” BioStar founder & senior managing director Dr. Louis Cannon said. “Mark’s knowledge, connections, tenacity, and unique ability to innately deconstruct complex situations into clear, actionable paths will greatly benefit our investors and limited partners, our startups, and most importantly, positively impact the lives of patients.”